547 related articles for article (PubMed ID: 18633127)
1. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
Akkasilpa S; Osiri M; Deesomchok U; Avihingsanon Y
J Med Assoc Thai; 2004 Sep; 87(9):1087-91. PubMed ID: 15516011
[TBL] [Abstract][Full Text] [Related]
4. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.
Reinders MK; van Roon EN; Houtman PM; Brouwers JR; Jansen TL
Clin Rheumatol; 2007 Sep; 26(9):1459-65. PubMed ID: 17308859
[TBL] [Abstract][Full Text] [Related]
5. Uricosuric medications for chronic gout.
Kydd AS; Seth R; Buchbinder R; Edwards CJ; Bombardier C
Cochrane Database Syst Rev; 2014 Nov; (11):CD010457. PubMed ID: 25392987
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
Perez-Ruiz F; Alonso-Ruiz A; Calabozo M; Herrero-Beites A; García-Erauskin G; Ruiz-Lucea E
Ann Rheum Dis; 1998 Sep; 57(9):545-9. PubMed ID: 9849314
[TBL] [Abstract][Full Text] [Related]
7. The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand.
Stamp LK; Haslett J; Frampton C; White D; Gardner D; Stebbings S; Taylor G; Grainger R; Kumar R; Kumar S; Kain T; Porter D; Corkill M; Cathro A; Metcalfe S; Wyeth J; Dalbeth N
Intern Med J; 2016 Sep; 46(9):1075-80. PubMed ID: 27391386
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients.
Hanvivadhanakul P; Akkasilpa S; Deesomchok U
J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S40-7. PubMed ID: 12188443
[TBL] [Abstract][Full Text] [Related]
9. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
[TBL] [Abstract][Full Text] [Related]
10. A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study
.
Zhou Q; Su J; Zhou T; Tian J; Chen X; Zhu J
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):163-168. PubMed ID: 27936522
[TBL] [Abstract][Full Text] [Related]
11. Allopurinol for chronic gout.
Seth R; Kydd AS; Buchbinder R; Bombardier C; Edwards CJ
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD006077. PubMed ID: 25314636
[TBL] [Abstract][Full Text] [Related]
12. [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol].
Ohno I; Okabe H; Yamaguchi Y; Saikawa H; Uetake D; Hikita M; Gomi H; Ichida K; Hosoya T
Nihon Jinzo Gakkai Shi; 2008; 50(4):506-12. PubMed ID: 18546882
[TBL] [Abstract][Full Text] [Related]
13. [Hyperuricemia and gout--treatment].
Gröbner W; Walter-Sack I
Dtsch Med Wochenschr; 2002 Feb; 127(5):210-3. PubMed ID: 11821994
[No Abstract] [Full Text] [Related]
14. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout.
Stamp LK; Chapman PT; Barclay ML; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
Ann Rheum Dis; 2017 Sep; 76(9):1522-1528. PubMed ID: 28314755
[TBL] [Abstract][Full Text] [Related]
15. Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study.
Lin HC; Daimon M; Wang CH; Ho Y; Uang YS; Chiang SJ; Wang LH
Int J Cardiol; 2017 Apr; 233():85-90. PubMed ID: 28202260
[TBL] [Abstract][Full Text] [Related]
16. [Effectiveness and tolerance of long-term uricosuric treatment].
Berg H
Z Gesamte Inn Med; 1990 Dec; 45(23):719-20. PubMed ID: 2102029
[TBL] [Abstract][Full Text] [Related]
17. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
Bardin T; Keenan RT; Khanna PP; Kopicko J; Fung M; Bhakta N; Adler S; Storgard C; Baumgartner S; So A
Ann Rheum Dis; 2017 May; 76(5):811-820. PubMed ID: 27821644
[TBL] [Abstract][Full Text] [Related]
18. [Long lasting normalization of uric acid after combination therapy with 300 mg allopurinol and 60 mg benzbromarone in patients with gout and hyperuricemia].
Matzkies F
Med Klin (Munich); 1992 Sep; 87(9):460-2. PubMed ID: 1406482
[TBL] [Abstract][Full Text] [Related]
19. [Chronic gout. Case report of a severe course of disease].
Boxberger F; Harsch IA; Brueckl WM; Hautmann M; Baum U; Hahn EG; Wein A
Med Klin (Munich); 2003 Nov; 98(11):646-7. PubMed ID: 14631540
[No Abstract] [Full Text] [Related]
20. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]